Highlights from the American College of Cardiology 49th Annual Scientific Sessions: March 12 to 15, 2000

References 

1. The EPISTENT investigators . Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade Lancet. 1998;352:87–92
   • Abstract
   • Full Text
   • Full-Text PDF (84 KB)
   • CrossRef
2. Henry TD, Annex BH, Azrin MA, et al.  Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor: the VIVA trial. [abstract] J Am Coll Cardiol. 1999;33(suppl A):384A
3. Hulley S, Grady D, Bush T, et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613
   • MEDLINE
   • CrossRef
4. The SYMPHONY investigators . Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet. 2000;355:337–345
   • Abstract
   • Full Text
   • Full-Text PDF (118 KB)
   • CrossRef
5. O’Neill WW. The Evaluation of Xemilofiban in ControllIng Thrombotic Events (EXCITE) trial: 30-day and six-month results. In: Presented at the 48th Scientific Sessions of the American College of Cardiology, New Orleans, Louisiana. March 7 to 10, 1999;
6. Cannon CP. Presented at the 48th Scientific Sessions of the American College of Cardiology, New Orleans, Louisiana,, Orbofiban in patients with unstable coronary syndromes (TIMI-16) preliminary results. March 7 to 10, 1999.;
7. The Bypass Angioplasty Revascularization Investigation (BARI) investigators . Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1999;335:217–225
   • MEDLINE
   • CrossRef
8. The BARI investigators . Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997;96:1761–1769
   • MEDLINE
9. National Heart, Lung, and Blood Institute (NHLBI) . Clinical alert: bypass over angioplasty for patients with diabetes. www.nlm.nih.gov/databases/alerts/bypass_diabetes.html21 Sept 1995;
10. Ferguson JJ. NHLBI BARI clinical alert on diabetics treated with angioplasty. [abstract] Circulation. 1995;92:3371
    • MEDLINE
11. Peterson ED, Anstrom KJ, McGuire DK. The influence of the BARI diabetic treatment alert on revascularization selection patterns: The NCN results. [abstract] In: J Am Coll Cardiol. 35:2000;p. 544A